Jazz Pharmaceuticals plc Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Jazz Pharmaceuticals plc (JAZZ) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $8.86 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-24
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $8.86M, a 18.67% decline from fiscal 2024.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $10.89M, a 22.73% decline from fiscal 2023.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $14.09M, a 4.35% increase from fiscal 2022.
- Jazz Pharmaceuticals plc effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $13.51M, a 32.18% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $8.86M 10-K · filed 2026-02-24 |
| 2024-12-31 | $10.89M 10-K · filed 2026-02-24 |
| 2023-12-31 | $14.09M 10-K · filed 2026-02-24 |
| 2022-12-31 | $13.51M 10-K · filed 2025-02-26 |
| 2021-12-31 | $19.91M 10-K · filed 2024-02-28 |
| 2020-12-31 | $8.60M 10-K · filed 2023-03-01 |
| 2019-12-31 | $8.32M 10-K · filed 2022-03-01 |
| 2014-12-31 | $4.20M 10-K · filed 2015-02-24 |
| 2013-12-31 | $2.50M 10-K · filed 2015-02-24 |
| 2012-12-31 | $873.00K 10-K · filed 2015-02-24 |
| 2011-12-31 | $670.00K 10-K · filed 2014-02-25 |
| 2010-12-31 | $1.08M 10-K · filed 2013-02-26 |
| 2009-12-31 | $1.40M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |